News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Applied Nanoscience Reports Positive H1N1, Rhinovirus Test Results and Strides Toward Commercialization of NanoFense Protective Face Mask



3/15/2010 10:32:44 AM

CARLSBAD, CA--(Marketwire - March 15, 2010) -

Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration company, today announced that it has received extremely positive test results on the effectiveness of the disposable NanoFense™ Protective Face Mask when challenged with the current swine influenza virus (H1N1). In addition, their proprietary NanoFense coating formulation proved to be equally effective when challenged directly with rhinovirus, the cause of the common cold. Both of the studies were conducted by a nationally recognized independent BSL-3 laboratory. The company expects to complete additional testing relating to an additional U.S. patent application in the next two weeks to further protect international efforts and the intellectual property portfolio already amassed.

Applied Nanoscience Inc. also announced it has successfully completed trial efforts to coat rolls of filter media specified by their Asia Pacific mask partner within the appropriate concentration range. This has further narrowed the timeframe for supplying hydrophobic media pre-coated with the company's NanoFense formulation, a proprietary antimicrobial nanoparticle filter coating developed by ANI. "The continued focus on specific efforts which directly lead to commercial revenues has put ANI in a very exciting position. We are working diligently to finalize the remaining details in a supply contract with our mask partner," stated Thomas K. Allen, President and CEO - ANI.

ANI continues to push forward on U.S. patent efforts tied to its NanoFense formulation as well as the NEFT™ platform.

The revolutionary disposable NanoFense Protective Face Mask will be made available as soon as possible in an effort to help protect people in some of the most heavily populated parts of the world. The company anticipates the reporting of related revenues to begin in the second quarter of 2010 as final strategic projects are completed. Applied Nanoscience HK Ltd. is now formally registered in Hong Kong as a subsidiary with banking functions in place to export the coated filter media. It will be sold in many of the countries where ANI has issued patents protecting their broad NEFT platform. The patent coverage includes three main methods of associating nanoparticles with filter media: (1) coating the filter media with a powder of nanoparticles, (2) impregnating the nanoparticles into the filter media, and (3) having pellets of nanoparticles located adjacent to the filter media.

About ANI

ANI is a marketer, developer and manufacturer of innovative nanotechnology-based air filtration products specifically targeted to eradicate bacteria, virus and fungi and is the owner of NEFT (Nanoparticle - Enhanced - Filtration - Technology), a broad platform with significant application potential in customer and industrial market segments geared to reducing the transmission of infectious pathogens. The NanoFense formulation can be applied to virtually any existing filter media in order to produce air filtration products which can offer broad protection against virus, bacteria and fungi.

For more information on the Company please visit: www.appliednanoscience.com.

Safe Harbor Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. ANI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes and other factors affecting such forward-looking information. The actual future plans and results of the Company could differ significantly from such forward-looking statements.


For further information, please contact:
Thomas K. Allen
President and CEO
Applied Nanoscience Inc.
(760) 434-2400

Joe Noel
Emerging Growth Research, LLP
(925) 922-2560


Read at BioSpace.com


comments powered by Disqus
   
Swine Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES